New Brain Biomarkers for Alzheimer’s Disease Detection Discovered

Scientists have developed a set of brain biomarkers that help predict which patients with Mild Cognitive Impairment have a higher risk of developing dementia.

A set of brain biomarkers that help predict which patients with Mild Cognitive Impairment (MCI) have an increased risk of developing dementia has been developed by a research team from the Complutense University of Madrid (UCM).

"In this work we find that two subnets, in theta and beta frequency bands, which involve fronto-temporal and fronto-occipital regions, are altered during the evolution of Alzheimer's Disease," says Mª Eugenia López García, researcher from the Cognitive Neuroscience group of the UCM and one of the authors of the study.

Dementia - Types, Causes, Symptoms, Diagnosis, Treatment
Dementia has become a very big concern as we have an aging population across the world. Dementia is also terrifying to us because of its disturbing symptoms and limited treatment options.

‘Patients with Mild Cognitive Impairment (MCI) who subsequently develop Alzheimer’s disease show an increase in synchrony but, as dementia develops, this synchronization decreases as a symptom of cortical network dysfunction.’

The research, published in Brain, takes hypersynchronization -increased connectivity between brain regions- as the main axis of changes and magnetoencephalography (MEG) as the tool to detect it.

In addition to the UCM Faculty of Psychology, the San Carlos Clinic hospital, the Laboratory of Cognitive and Computational Neuroscience (UCM-UPM) of the Centre for Biomedical Technology, the University of the Balearic Islands and the University of La Laguna (Tenerife) also participate in the project.

Model X

Test Your Knowledge on Dementia
Dementia is a leading cause of disability in older people. It is a condition where brain cells are permanently damaged or functionally impaired. Till 2015, about 47.5 million people suffer from dementia across the globe. There are various conditions that lead to dementia and it is important to get aware of its causes, effects and vulnerability. So how much do you know dementia? Take our advanced quiz and learn!

Mild Cognitive Impairment is an intermediate phase between what is considered normal aging and dementia, with a rate of 15 % of patients per year moving from this stage to Alzheimer's. Therefore, the early diagnosis of MCI, and especially the distinction of patients with MCI who will end up suffering from AD "would help to diagnose and establish a prognosis and make a system for evaluating new pharmacological or non-pharmacological interventions available," says López. Garcia

To carry out this study, the researchers recruited 54 patients with MCI for three years (from an initial sample of 145) who were monitored every six months for three years, and magnetoencephalography records were implemented to measure the magnetic fields that our brain generates both at the beginning (pre phase) and at the end of the study (post phase).

Alzheimer's Risk Assessment Calculator
Alzheimer’s Risk Assessment Calculator is a tool to measure the level of Alzheimer’s disease. It also provides tips to prevent Alzheimer’s disease.

Techniques for estimating brain synchronization were applied to these records: these allow us to determine the way in which different brain regions communicate with each other.

At the end of the study, 27 patients remained as MCI (stable MCI, MCIs) and the other half converted to Alzheimer's (MCI converters, MCIc). The model developed in this study had a success rate of 96.2 %.

Brain Depression
Interactive section of Medindia provides information about chemistry of Brain depression

"The synchronization results obtained in the pre and post phases have allowed us to elaborate an explanatory model, which we have called "model X", which shows that hypersynchronization predicts the conversion in the MCIc group in the pre phase, demonstrating a decrease in synchronization in this group in the post phase. On the contrary, the MCIs group shows an inverse synchronization pattern in both stages," explains the UCM expert.

The World Health Organization (WHO) estimates that 35.6 million people currently live with dementia, understood as any neurodegenerative disease associated with age. Predictions suggest that the number of people affected will double by 2030 and triple by 2050, with AD being the most prevalent.

"Having this early and non-invasive biomarker can help people to understand this terrible disease. We as researchers have the objective of being useful and being able to make discoveries that can help improve our knowledge of this complex disease," concludes López García. Along with her, the investigators Sandra Pusil, María Eugenia López, Pablo Cuesta, Ricardo Bruña, Ernesto Pereda and Fernando Maestú were part of this research team.

Source-Eurekalert